Medicare Enrolled
Dr. Steven Bromley, MD
Neurology · Audubon, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bromley from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bromley?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bromley
Dr. Steven Bromley is a neurology specialist in Audubon, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Bromley performed 85,706 Medicare services across 1,251 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bromley received a total of $1,593,275 from 98 pharmaceutical and/or device companies across 3311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bromley is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in NJ
$1,593,275 industry payments
Medicare Practice Summary
Medicare Utilization ↗85,706
Medicare services
Top 1% in NJ for neurology
1,251
Unique beneficiaries
$34
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,511 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Ocrelizumab infusion (Ocrevus) for MS | 34,500 | $47 | $108 |
| Injection, eptinezumab-jjmr, 1 mg | 25,900 | $13 | $30 |
| Privigen immune globulin injection, 500 mg An intravenous injection of Privigen, a non-lyophilized immune globulin product, administered in a 500 mg dose. |
17,855 | $37 | $84 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 2,680 | $37 | $84 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
1,262 | $17 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
712 | $54 | $150 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
535 | $4 | $11 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
525 | $1 | $8 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
349 | $97 | $233 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
290 | $137 | $314 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
284 | $24 | $100 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
166 | $106 | $350 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
119 | $11 | $56 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
117 | $1 | $10 |
| New patient office visit, complex (60-74 min) | 113 | $171 | $446 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
80 | $61 | $157 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
80 | $1 | $10 |
| Anti-nausea injection (ondansetron/Zofran) | 76 | $0 | $0 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
29 | $0 | $10 |
| Trigger point injection, 3 or more muscles Injection of medication into three or more specific muscle trigger points to relieve pain. |
22 | $48 | $140 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $117 | $355 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.4% high complexity
55.7% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,593,275
Total received (2018-2024)
Avg $227,611/year across 7 years
Top 0% in NJ for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
98
Companies
3,311
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,575,709 (98.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,566 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$305,299
2023
$235,671
2022
$228,187
2021
$172,329
2020
$147,687
2019
$233,864
2018
$270,238
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Otsuka America Pharmaceutical, Inc.
$83,198
EMD Serono, Inc.
$49,285
ABBVIE INC.
$32,778
E.R. Squibb & Sons, L.L.C.
$32,181
Lundbeck LLC
$29,200
UCB, Inc.
$22,973
Genentech USA, Inc.
$14,992
Eisai Inc.
$12,342
Lilly USA, LLC
$10,748
Alexion Pharmaceuticals, Inc.
$8,976
TG Therapeutics, Inc.
$3,352
Celgene Corporation
$2,717
PFIZER INC.
$436
ACADIA Pharmaceuticals Inc
$277
ANI Pharmaceuticals, Inc.
$179
Amneal Pharmaceuticals LLC
$176
Biogen, Inc.
$176
SCILEX PHARMACEUTICALS INC.
$167
ARGENX US, INC.
$96
Kyowa Kirin, Inc.
$95
Takeda Pharmaceuticals U.S.A., Inc.
$95
Axsome Therapeutics, Inc.
$93
Mallinckrodt Hospital Products Inc.
$77
Amgen Inc.
$73
Neurocrine Biosciences, Inc.
$69
Abbott Laboratories
$60
MDD US Operations, LLC
$58
Life Molecular Imaging Ltd
$57
GENZYME CORPORATION
$56
Teva Pharmaceuticals USA, Inc.
$51
Merz Pharmaceuticals, LLC
$42
Vanda Pharmaceuticals Inc.
$36
Genentech, Inc.
$33
Ipsen Biopharmaceuticals, Inc
$32
HARMONY BIOSCIENCES LLC
$27
Boston Scientific Corporation
$24
IDORSIA PHARMACEUTICALS US INC
$16
Averitas Pharma Inc.
$16
AstraZeneca Pharmaceuticals LP
$15
Grifols USA, LLC
$13
Corium, LLC
$13
Top 3 companies account for 54.1% of 2024 payments
All-time payments by company (2018-2024) ›
EMD Serono, Inc.
$160,464
E.R. Squibb & Sons, L.L.C.
$145,867
Celgene Corporation
$123,897
Biogen, Inc.
$117,427
GENZYME CORPORATION
$114,627
Alexion Pharmaceuticals, Inc.
$111,958
Genentech USA, Inc.
$111,850
Otsuka America Pharmaceutical, Inc.
$109,699
Lundbeck LLC
$89,620
Novartis Pharmaceuticals Corporation
$71,399
Amgen Inc.
$56,489
AbbVie Inc.
$47,522
ABBVIE INC.
$46,555
Avanir Pharmaceuticals, Inc.
$45,263
TG THERAPEUTICS, INC.
$39,561
Allergan, Inc.
$37,674
UCB, Inc.
$28,482
Biohaven Pharmaceuticals, Inc.
$26,305
ARGENX US, INC.
$16,013
Teva Pharmaceuticals USA, Inc.
$15,382
Allergan Inc.
$14,855
Eisai Inc.
$12,504
Lilly USA, LLC
$11,156
Acorda Therapeutics, Inc
$10,876
Biohaven Pharmaceutical Holding Company Ltd.
$9,531
NOVARTIS PHARMACEUTICALS CORPORATION
$5,635
TG Therapeutics, Inc.
$3,352
PFIZER INC.
$987
ACADIA Pharmaceuticals Inc
$406
Amneal Pharmaceuticals LLC
$401
Mallinckrodt Hospital Products Inc.
$400
ANI Pharmaceuticals, Inc.
$388
IMPEL PHARMACEUTICALS INC.
$375
Supernus Pharmaceuticals, Inc.
$315
Takeda Pharmaceuticals U.S.A., Inc.
$313
Neurocrine Biosciences, Inc.
$311
Kyowa Kirin, Inc.
$304
Sunovion Pharmaceuticals Inc.
$254
Axsome Therapeutics, Inc.
$250
Janssen Pharmaceuticals, Inc
$245
Averitas Pharma Inc.
$195
MDD US Operations, LLC
$179
Harmony Biosciences LLC
$169
SK Life Science, Inc.
$168
SCILEX PHARMACEUTICALS INC.
$167
Horizon Therapeutics plc
$162
JAZZ PHARMACEUTICALS INC.
$160
Exeltis, USA Inc.
$158
Neuronetics, Inc.
$152
Upsher-Smith Laboratories LLC
$141
ARBOR PHARMACEUTICALS, INC.
$136
GRT US Holding, Inc.
$117
Neurelis, Inc.
$116
GE HealthCare
$115
Currax Pharmaceuticals LLC
$114
Merz Pharmaceuticals, LLC
$113
Jazz Pharmaceuticals Inc.
$103
Vanda Pharmaceuticals Inc.
$92
Boston Scientific Corporation
$90
Abbott Laboratories
$89
HARMONY BIOSCIENCES LLC
$88
Philips Electronics North America Corporation
$87
CSL Behring
$87
US WorldMeds, LLC
$84
MERZ NORTH AMERICA, INC.
$81
Adlon Therapeutics L.P.
$81
AstraZeneca Pharmaceuticals LP
$72
Almatica Pharma LLC
$67
Merck Sharp & Dohme LLC
$64
Scilex Pharmaceuticals Inc.
$63
Tris Pharma Inc
$57
Life Molecular Imaging Ltd
$57
SANOFI-AVENTIS U.S. LLC
$54
Mallinckrodt Enterprises LLC
$54
Azurity Pharmaceuticals, Inc.
$49
IDORSIA PHARMACEUTICALS US INC
$47
Ipsen Biopharmaceuticals, Inc
$44
UPSHER-SMITH LABORATORIES LLC
$39
Mitsubishi Tanabe Pharma America, Inc.
$39
Nevro Corp.
$38
Genentech, Inc.
$33
Corium, LLC
$30
EISAI INC.
$30
ITI, Inc.
$30
Banner Life Sciences, LLC
$29
Merz North America, Inc.
$28
Grifols USA, LLC
$27
BOSTON SCIENTIFIC CORPORATION
$23
CATALYST PHARMACEUTICALS, INC.
$18
W. L. Gore & Associates, Inc.
$17
Octapharma USA, Inc.
$15
Avion Pharmaceuticals
$15
Collegium Pharmaceutical, Inc.
$15
Strongbridge US INC.
$14
Bayer HealthCare Pharmaceuticals Inc.
$13
Merck Sharp & Dohme Corporation
$13
Impax Laboratories, Inc.
$12
Shire North American Group Inc
$12
Top 3 companies account for 27.0% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · ADHANSIA XR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMYVID · APOKYN · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aimovig · Austedo XR · Azstarys · BAFIERTAM · BELSOMRA · BOTOX · BOTOX THERAPEUTIC · BRILINTA · BRIUMVI · Belbuca · Betaseron · Briviact · CAPLYTA · COPAXONE · DYSPORT · Dayvigo · Dhivy · Dyanavel XR · Dysport · EMGALITY · EVENITY · EVUSHELD · FIRDAPSE · Fycompa · GAMMAGARD · GILENYA · GOCOVRI · GORE CARDIOFORM Septal Occluder · GRALISE · Gamunex-C · General - DBS · Gocovri · HETLIOZ · HYQVIA · Hizentra · Horizant · INBRIJA · INFINITY · INGREZZA · KEVEYIS · KISUNLA · KRYSTEXXA · KYNMOBI · LEMTRADA · LYRICA · LYVISPAH · Leqembi · MAVENCLAD · MAYZENT · MS DISEASE STATE · MYOBLOC · Mavenclad · NAMZARIC · NAPRELAN · NEURACEQ · NEUROSTAR TMS THERAPY SYSTEM · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nourianz · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONGENTYS 50MG CAPSULES 30 · ONZETRA XSAIL · ONZETRA Xsail · OXTELLAR XR · Ocrevus · Ocrevus Zunovo · Ongentys · Ozanimod · PANZYGA · PAXLOVID · PLEGRIDY · PONVORY · PURIFIED CORTROPHIN GEL · Ponvory · QULIPTA · QUTENZA · QUVIVIQ · Qutenza · RADICAVA · REXULTI · RYTARY · Radicava · Rebif · Rystiggo · SOLIRIS · SUNOSI · Senza · Senza Spinal Cord Stimulation System · Soliris · Strensiq · Sunosi · TECFIDERA · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TRINTELLIX · TROKENDI XR · TYSABRI · Trudhesa · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VERCISE · VRAYLAR · VUMERITY · VYEPTI · VYVANSE · VYVGART · VYVGART HYTRULO · Vercise · Vimpat · WAKIX · Wakix · XEOMIN · XYWAV · Xadago · Xeomin · Xyrem · ZEPOSIA · ZTLido · Zilbrysq · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for neurology in NJ.
Geographic Context
Neurologists within 10 mi
488
Per 100K population
93.1
County median income
$86,384
Nearest hospital
COOPER UNIVERSITY HOSPITAL
3.7 mi
3.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bromley is a mixed practice specialist, with above-average Medicare volume (top 1% in NJ), with speaking/promotional industry engagement in the top 0% of NJ peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bromley experienced with ocrelizumab infusion (ocrevus) for ms?
Based on Medicare claims data, Dr. Bromley performed 34,500 ocrelizumab infusion (ocrevus) for ms services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bromley receive payments from pharmaceutical companies?
Yes. Dr. Bromley received a total of $1,593,275 from 98 companies across 3,311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bromley's costs compare to other neurologists in Audubon?
Dr. Bromley's average Medicare payment per service is $34. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bromley) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Audubon
Browse neurologists in Audubon ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in NJ
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in NJ
Which NJ neurologists receive the most from drug and device companies.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology